降钙素原、C反应蛋白和白蛋白水平指导下的抗生素在脓毒症中的使用疗效评估
Assessment of the Efficacy of Procalcitonin, C-Reactive Protein, and Albumin Levels-guided Antibiotics Use in Sepsis.
作者信息
Cao Junyue, Sun Yuchao
机构信息
Prevention and Health Care Department, Wujing Community Health Center, affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200241, China.
Physical Education, Beijing Sport University, Beijing 100084, China.
出版信息
Mediterr J Hematol Infect Dis. 2025 Sep 1;17(1):e2025060. doi: 10.4084/MJHID.2025.060. eCollection 2025.
BACKGROUND
Efficient management of sepsis requires precise antibiotic therapy. This study examines the efficacy of guiding such therapy using Procalcitonin (PCT), C-Reactive Protein (CRP), and albumin levels.
METHODS
A total of 127 adult sepsis patients were assigned to either standard care or a biomarker-guided group where antibiotic use was adjusted based on biomarker levels.
RESULTS
The biomarker-guided approach significantly reduced the duration of antibiotic therapy (9.0 vs. 10.5 days, =0.04) and expedited antibiotic de-escalation. Hospital costs were lower in the biomarker-guided group (20,000 vs. 24,000 CNY, =0.04), though reductions in secondary infections did not reach statistical significance. There was no significant difference in 28-day mortality rates.
CONCLUSION
Biomarker-guided antibiotic therapy can enhance the efficiency of treatment in sepsis, reducing both duration and cost without impacting patient safety. These findings suggest the potential benefits of incorporating biomarkers into standard sepsis management protocols.
背景
脓毒症的有效管理需要精确的抗生素治疗。本研究考察了使用降钙素原（PCT）、C反应蛋白（CRP）和白蛋白水平来指导此类治疗的疗效。
方法
总共127名成年脓毒症患者被分配至标准治疗组或生物标志物指导组，后者根据生物标志物水平调整抗生素使用。
结果
生物标志物指导的方法显著缩短了抗生素治疗时长（9.0天对10.5天，P=0.04），并加快了抗生素降阶梯治疗。生物标志物指导组的住院费用更低（20,000元对24,000元，P=0.04），尽管继发感染的减少未达到统计学显著性。28天死亡率无显著差异。
结论
生物标志物指导的抗生素治疗可提高脓毒症的治疗效率，在不影响患者安全的情况下缩短治疗时长并降低费用。这些发现表明将生物标志物纳入标准脓毒症管理方案具有潜在益处。
Zotero 插件